Hospital
Banner Lassen Medical Center
Banner Lassen Medical Center was paid $4.70M by Medicaid between Jan 2018 and Nov 2024, across 113 billing codes. Its largest line is 99283, emergency room visit (moderate) — 28% of everything it billed.
33Billing provider infoBANNER LASSEN MEDICAL CENTER
SUSANVILLE, CA 96130
SUSANVILLE, CA 96130
33aNPI1538197231assigned 06/29/2006
33bProvider typeCritical Access Hospital
28Total paid$4.70M
24GClaims136,019
24DCodes billed113
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in California
Rank by total paid#11 of 30
Median peer was paid$3.14M
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 19,927 | $828K | |
| 2019 | 20,937 | $693K | |
| 2020 | 18,217 | $593K | |
| 2021 | 18,898 | $689K | |
| 2022 | 21,051 | $786K | |
| 2023 | 24,266 | $766K | |
| 2024incomplete | 12,723 | $349K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 28% | 16,970 | 14,888 | $1.31M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 21% | 11,888 | 10,733 | $968K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.2% | 6,105 | 2,045 | $245K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.3% | 2,581 | 2,446 | $203K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 4.0% | 3,315 | 1,201 | $190K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 3.0% | 801 | 799 | $142K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.0% | 418 | 412 | $140K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 2.6% | 1,290 | 1,252 | $121K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.4% | 3,130 | 2,849 | $114K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.3% | 2,072 | 1,904 | $110K |
| 80053 | Comprehensive metabolic panel | 1.9% | 11,913 | 10,824 | $91K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.6% | 2,092 | 1,909 | $76K |
101 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 403 | $75K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 12,590 | $70K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 1,766 | $65K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 2,137 | $51K |
| 99201 | 1.1% | 245 | $51K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.1% | 4,319 | $50K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 332 | $33K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 346 | $29K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 960 | $28K |
| 80061 | Lipid panel | <1% | 3,000 | $27K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,989 | $27K |
| J3490 | Unclassified drugs | <1% | 2,294 | $25K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,231 | $21K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,375 | $20K |
| 99284 | Emergency room visit (serious) | <1% | 257 | $19K |
| 87631 | <1% | 333 | $18K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 398 | $18K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,068 | $17K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 258 | $16K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 749 | $15K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,199 | $14K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 103 | $14K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,066 | $14K |
| 84484 | <1% | 1,687 | $13K | |
| 83690 | <1% | 2,516 | $13K | |
| J2704 | Injection, propofol, 10 mg | <1% | 633 | $12K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 444 | $12K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,971 | $12K |
| 84439 | <1% | 1,845 | $11K | |
| 80305 | <1% | 841 | $11K | |
| 81001 | <1% | 3,735 | $10K | |
| 73030 | <1% | 275 | $10K | |
| 72100 | <1% | 195 | $9K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 116 | $8K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 77 | $8K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 259 | $8K |
| 73610 | <1% | 174 | $7K | |
| 81025 | <1% | 2,334 | $7K | |
| 73630 | <1% | 166 | $7K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 71 | $6K |
| 73110 | <1% | 151 | $6K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 680 | $6K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 59 | $5K |
| 85027 | <1% | 1,068 | $5K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 187 | $5K |
| 85610 | <1% | 1,714 | $5K | |
| 0450 | Emergency room services | <1% | 49 | $4K |
| 86769 | <1% | 147 | $4K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 586 | $4K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 486 | $4K |
| 87400 | <1% | 473 | $3K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 43 | $3K |
| 73130 | <1% | 79 | $3K | |
| 81003 | <1% | 1,621 | $3K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 13 | $3K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 113 | $3K |
| 83605 | <1% | 365 | $3K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 61 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 542 | $3K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 102 | $3K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 40 | $3K |
| 82947 | <1% | 669 | $3K | |
| 87081 | <1% | 525 | $2K | |
| 87430 | <1% | 292 | $2K | |
| 86140 | <1% | 561 | $2K | |
| 87186 | <1% | 309 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 251 | $2K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 12 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 126 | $1K |
| 76830 | Ultrasound, transvaginal | <1% | 13 | $1K |
| 83735 | <1% | 289 | $1K | |
| 73562 | <1% | 37 | $1K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 32 | $1K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 37 | $982.83 |
| 87807 | <1% | 112 | $929.90 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 50 | $656.16 |
| 99070 | <1% | 18 | $639.00 | |
| 85652 | <1% | 338 | $634.25 | |
| 82746 | <1% | 54 | $536.55 | |
| 86901 | <1% | 272 | $524.06 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 119 | $489.64 |
| 86850 | <1% | 246 | $489.04 | |
| 85730 | <1% | 90 | $487.59 | |
| 86900 | <1% | 247 | $458.98 | |
| 87040 | <1% | 62 | $450.00 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 15 | $386.56 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 15 | $385.32 |
| 83880 | <1% | 15 | $373.86 | |
| 86803 | <1% | 38 | $285.08 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 24 | $255.54 |
| 83540 | <1% | 41 | $184.34 | |
| 87077 | <1% | 31 | $172.86 | |
| 83550 | <1% | 26 | $143.26 | |
| 86592 | <1% | 52 | $133.26 | |
| 84481 | <1% | 13 | $98.52 | |
| 84436 | <1% | 13 | $62.66 | |
| 86038 | <1% | 12 | $55.15 | |
| 84100 | <1% | 12 | $37.07 | |
| 87340 | <1% | 13 | $24.09 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 14 | $15.04 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 13 | $0.24 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDUGGER, SANDRA (CEO)
Parent organizationBANNER HEALTH